首頁 > 市場調查報告書 > 製藥

動物用醫藥

市場調查報告書

商品編碼

1964184

伴侶動物術後疼痛管理治療市場－全球產業規模、佔有率、趨勢、機會、預測：按動物種類、產品、給藥途徑、地區和競爭格局分類，2021-2031年

Companion Animal Postoperative Pain Management Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Animal, By Product, By Route of Administration, By Region & Competition, 2021-2031F

出版日期: 2026年01月19日 | 出版商:

TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球伴侶動物術後疼痛管理療法市場預計將從 2025 年的 2.1456 億美元成長到 2031 年的 3.4466 億美元，複合年成長率達到 8.22%。

此領域涵蓋用於緩解寵物術後急性疼痛的藥品，包括非類固醇消炎劑和鴉片類藥物。市場成長的主要驅動力是獸醫院進行的整形外科和牙科手術數量的增加，以及動物福利臨床標準的提升。此外，獸醫醫療基礎設施的改善和新型給藥系統的引入，提高了鎮痛方案的有效性，也是推動市場成長的因素。

市場概覽
預測期	2027-2031
市場規模：2025年	2.1456億美元
市場規模：2031年	3.4466億美元
複合年成長率：2026-2031年	8.22%
成長最快的細分市場	非類固醇消炎劑（NSAIDs）
最大的市場	北美洲

飼主在寵物健康方面承擔的巨大經濟負擔進一步推動了市場成長。根據美國寵物用品協會（APPA）統計，2024年美國獸醫保健支出和產品銷售額將達398億美元。然而，儘管支出強勁，但複雜外科手術和必要的疼痛管理通訊協定的高昂費用仍然是一項重大挑戰。這些費用可能會使經濟拮据的飼主無法獲得最佳護理，這可能會阻礙市場的進一步擴張。

市場促進因素

伴侶動物飼養和領養率的不斷提高是全球伴侶動物術後疼痛管理治療市場的主要驅動力。隨著寵物數量的成長，需要獸醫護理的動物數量（包括整形外科疾病、軟組織損傷和牙科問題的手術治療）自然也在增加。這種激增直接催生了對術後止痛藥物的需求，而患者數量的增加也需要增加止痛藥的處方量。此外，人類與動物之間日益緊密的聯繫促使飼主尋求更先進的醫療護理，以確保寵物能夠獲得與人類相當的疼痛緩解。根據英國寵物食品公司於2024年3月發布的《2024年寵物數據報告》，英國的寵物數量已達3,600萬隻，60%的家庭擁有伴侶動物，這顯著擴大了有效治療方案的目標市場。

鎮痛藥的研發和藥物遞送系統的進步是第二個關鍵促進因素，從根本上改變了臨床治療通訊協定。業界正從傳統的短效鴉片類藥物和非類固醇消炎劑轉向長效標靶治療，例如單株抗體。這些療法提高了慢性疼痛和術後疼痛的安全性和藥物順從性。這些創新使獸醫能夠更頻繁、更長時間地開立疼痛管理處方。碩騰公司（Zoetis）於2024年11月發布的2024年第三季財報清晰地展現了這一趨勢，該財報顯示，其用於治療骨關節炎疼痛的單株抗體產品系列（包括利寶利（Librela）和索樂西亞（Solensia））的全球收入成長了97%。此外，該領域強勁的財務狀況也為持續創新提供了支持。 2024年2月，禮來動物保健公司（Elanco Animal Health）宣布2023年全年銷售額達44.17億美元，顯示該公司擁有強大的投資能力，用於開發下一代獸用治療藥物。

市場挑戰

先進的外科手術及其後續疼痛管理通訊協定的高成本是全球伴侶動物術後疼痛管理藥物市場成長的主要障礙。經濟拮据的寵物飼主往往無力負擔寵物必要的整形外科或牙科手術費用。由於術後疼痛藥物的需求與手術數量直接相關，手術數量的減少會立即縮小這些藥物的潛在市場規模。

因此，這種經濟壓力導致飼主推遲或放棄獸醫治療，從而縮小了處方箋止痛藥的基本客群。近期業界數據顯示獸醫服務使用率下降，也印證了這個趨勢。根據美國獸醫學會（AVMA）的數據，2023年8月至2024年8月期間，全美動物醫院的就診量下降了2.3%。就診量的下降表明，不斷上漲的費用導致飼主不願尋求專業醫療服務，從而減少了獸醫開立和使用術後止痛藥的機會。

市場趨勢

全球伴侶動物術後疼痛管理市場正迅速重塑臨床實踐，而減少鴉片類藥物的使用以及採用非鴉片類藥物療法的趨勢日益顯著。這一趨勢的主要促進因素是鴉片類藥物處方監管力度加大以及持續的供應鏈不穩定，這些因素威脅著受監管獸藥的供應。因此，臨床醫師正轉向多重藥物合併治療方案，優先使用非類固醇消炎劑（NSAIDs）、局部麻醉劑和α2促效劑，以確保有效鎮痛的同時，最大限度地減少對全身性通訊協定類藥物的依賴。供應限制凸顯了這項轉變的迫切性。根據美國系統藥劑師協會（ASHP）2024年12月發布的藥品短缺統計數據，美國共發生214起藥品短缺事件，其中鴉片類鎮痛藥的供應中斷尤為嚴重，迫使醫療專業人員採取替代治療策略。

同時，脂質體包裹藥物技術正成為延長術後鎮痛持續時間的創新方法。諸如脂質體Bupivacaine等先進製劑，只需單次局部麻醉劑即可在數天內持續釋放活性成分，覆蓋關鍵的術後72小時，無需導管或重複注射。這項技術解決了寵物依從性問題，並減輕了寵物在康復期間頻繁用藥的壓力。投資這些專業給藥平台的公司取得的商業性成功，也印證了這個市場趨勢。根據禮來動物保健公司（Elanco Animal Health）於2024年11月發布的2024年第三季財報，該公司寵物保健業務營收達4.86億美元，再次印證了其專業外科和疼痛管理產品組合（包括先進的長效療法）的穩健財務永續性。

The Global Companion Animal Postoperative Pain Management Therapeutics Market is projected to expand from USD 214.56 Million in 2025 to USD 344.66 Million by 2031, achieving a compound annual growth rate of 8.22%. This sector comprises pharmaceutical agents, including non-steroidal anti-inflammatory drugs and opioids, designed to alleviate acute pain in pets following surgical interventions. The market is primarily driven by the rising volume of orthopedic and dental procedures in veterinary clinics, alongside elevated clinical standards for animal welfare. Furthermore, the growth is supported by improvements in veterinary infrastructure and the introduction of novel drug delivery systems that enhance the effectiveness of pain relief solutions.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 214.56 Million
Market Size 2031	USD 344.66 Million
CAGR 2026-2031	8.22%
Fastest Growing Segment	NSAIDs
Largest Market	North America

Significant financial commitment from pet owners regarding animal health further reinforces market progress. According to the American Pet Products Association, United States expenditure on veterinary care and product sales reached $39.8 billion in 2024. However, despite this strong spending, the high costs associated with complex surgical interventions and necessary pain management protocols pose a substantial challenge. These expenses can restrict access to optimal care for economically constrained pet owners, thereby potentially hindering broader expansion of the market.

Market Driver

Increasing rates of companion animal ownership and adoption serve as a primary catalyst for the Global Companion Animal Postoperative Pain Management Therapeutics Market. As the pet population grows, there is a natural rise in the absolute number of animals requiring veterinary care, including surgeries for orthopedic conditions, soft tissue injuries, and dental diseases. This surge generates a direct demand for postoperative pain therapeutics, as a larger patient base necessitates a higher volume of analgesic prescriptions. Additionally, the strengthening human-animal bond drives owners to seek advanced medical care, ensuring their pets receive pain relief comparable to human standards. According to the 'Pet Data Report 2024' by UK Pet Food in March 2024, the United Kingdom's pet population reached 36 million, with 60% of households owning a companion animal, significantly widening the addressable market for effective therapeutic solutions.

Advancements in analgesic drug development and delivery systems constitute a second critical driver, fundamentally reshaping clinical treatment protocols. The industry is transitioning from traditional short-acting opioids and non-steroidal anti-inflammatory drugs toward long-acting, targeted therapies such as monoclonal antibodies, which offer enhanced safety and compliance for chronic and postoperative pain. These innovations encourage veterinarians to prescribe pain management more frequently and for extended durations. This trend is highlighted by Zoetis's 'Third Quarter 2024 Financial Results' in November 2024, which reported that their monoclonal antibody portfolio for osteoarthritis pain, including Librela and Solensia, achieved 97% operational revenue growth globally. Furthermore, the sector's robust financial health supports continued innovation; Elanco Animal Health reported full-year 2023 revenue of $4.417 billion in February 2024, underscoring the significant investment capacity available for developing next-generation veterinary therapeutics.

Market Challenge

The high cost associated with advanced surgical interventions and subsequent pain management protocols represents a significant barrier to the growth of the Global Companion Animal Postoperative Pain Management Therapeutics Market. When veterinary care becomes financially prohibitive, economically constrained pet owners are often compelled to decline necessary orthopedic or dental surgeries for their animals. Since the demand for postoperative pain therapeutics is directly linked to the volume of surgical procedures performed, any reduction in surgical caseloads immediately diminishes the total addressable market for these pharmaceutical agents.

Consequently, this financial pressure forces owners to delay or abandon potential veterinary treatments, effectively contracting the customer base for prescription pain relief solutions. This trend is evident in recent industry data showing a decline in veterinary utilization. According to the American Veterinary Medical Association, data collected between August 2023 and August 2024 indicated a 2.3% decrease in patient visits across veterinary practices in the United States. This drop in engagement suggests that rising costs are causing owners to forego professional care, thereby reducing the opportunities for veterinarians to prescribe and administer postoperative analgesics.

Market Trends

The shift toward opioid-sparing and non-opioid therapeutics is rapidly redefining clinical practices within the Global Companion Animal Postoperative Pain Management Therapeutics Market. This trend is primarily driven by increasing regulatory scrutiny on opioid prescriptions and persistent supply chain instabilities that threaten the availability of controlled substances for veterinary use. As a result, clinicians are pivoting toward multimodal protocols that prioritize non-steroidal anti-inflammatory drugs (NSAIDs), local anesthetics, and alpha-2 agonists to minimize reliance on systemic opioids while ensuring effective analgesia. The urgency of this transition is highlighted by supply constraints; according to the American Society of Health-System Pharmacists (ASHP) in their December 2024 'Drug Shortages Statistics', there were 214 active drug shortages in the United States, with significant disruptions in opioid analgesics, compelling practitioners to adopt alternative therapeutic strategies.

Simultaneously, the development of liposome-encapsulated drug technologies is emerging as a transformative approach for extending the duration of postoperative pain relief. These advanced formulations, such as liposomal bupivacaine, allow for a single administration of a local anesthetic that releases the active ingredient over several days, covering the critical 72-hour post-surgical window without the need for catheters or repeated injections. This technology addresses compliance challenges and reduces the stress associated with frequent medication administration in recovering pets. The commercial success of companies investing in these specialized delivery platforms validates this market trajectory; according to Elanco Animal Health's 'Third Quarter 2024 Financial Results' in November 2024, the company reported Pet Health revenue of $486 million, reinforcing the robust financial viability of its specialized surgical and pain management portfolio which includes advanced long-acting therapeutics.

Key Market Players

Zoetis Inc.
Merck & Co., Inc.
Elanco Animal Health Inc.
Ceva Sante Animale S.A.
Boehringer Ingelheim International GmbH
Norbrook Laboratories
Dechra Pharmaceuticals PLC
Chanelle Pharma
Bimeda Holdings Limited
VETOQUINOL S.A.

Report Scope

In this report, the Global Companion Animal Postoperative Pain Management Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Companion Animal Postoperative Pain Management Therapeutics Market, By Animal

Dogs
Cats
Horses
Others

Companion Animal Postoperative Pain Management Therapeutics Market, By Product

NSAIDs
Anesthetics
Opioids
Others

Companion Animal Postoperative Pain Management Therapeutics Market, By Route of Administration

Oral
Injectable

Companion Animal Postoperative Pain Management Therapeutics Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Companion Animal Postoperative Pain Management Therapeutics Market.

Available Customizations:

Global Companion Animal Postoperative Pain Management Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Companion Animal Postoperative Pain Management Therapeutics Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Animal (Dogs, Cats, Horses, Others)
- 5.2.2. By Product (NSAIDs, Anesthetics, Opioids, Others)
- 5.2.3. By Route of Administration (Oral, Injectable)
- 5.2.4. By Region
- 5.2.5. By Company (2025)
5.3. Market Map

6. North America Companion Animal Postoperative Pain Management Therapeutics Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Animal
- 6.2.2. By Product
- 6.2.3. By Route of Administration
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Companion Animal Postoperative Pain Management Therapeutics Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Animal
    - 6.3.1.2.2. By Product
    - 6.3.1.2.3. By Route of Administration
- 6.3.2. Canada Companion Animal Postoperative Pain Management Therapeutics Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Animal
    - 6.3.2.2.2. By Product
    - 6.3.2.2.3. By Route of Administration
- 6.3.3. Mexico Companion Animal Postoperative Pain Management Therapeutics Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Animal
    - 6.3.3.2.2. By Product
    - 6.3.3.2.3. By Route of Administration

7. Europe Companion Animal Postoperative Pain Management Therapeutics Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Animal
- 7.2.2. By Product
- 7.2.3. By Route of Administration
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Companion Animal Postoperative Pain Management Therapeutics Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Animal
    - 7.3.1.2.2. By Product
    - 7.3.1.2.3. By Route of Administration
- 7.3.2. France Companion Animal Postoperative Pain Management Therapeutics Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Animal
    - 7.3.2.2.2. By Product
    - 7.3.2.2.3. By Route of Administration
- 7.3.3. United Kingdom Companion Animal Postoperative Pain Management Therapeutics Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Animal
    - 7.3.3.2.2. By Product
    - 7.3.3.2.3. By Route of Administration
- 7.3.4. Italy Companion Animal Postoperative Pain Management Therapeutics Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Animal
    - 7.3.4.2.2. By Product
    - 7.3.4.2.3. By Route of Administration
- 7.3.5. Spain Companion Animal Postoperative Pain Management Therapeutics Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Animal
    - 7.3.5.2.2. By Product
    - 7.3.5.2.3. By Route of Administration

8. Asia Pacific Companion Animal Postoperative Pain Management Therapeutics Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Animal
- 8.2.2. By Product
- 8.2.3. By Route of Administration
- 8.2.4. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Companion Animal Postoperative Pain Management Therapeutics Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Animal
    - 8.3.1.2.2. By Product
    - 8.3.1.2.3. By Route of Administration
- 8.3.2. India Companion Animal Postoperative Pain Management Therapeutics Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Animal
    - 8.3.2.2.2. By Product
    - 8.3.2.2.3. By Route of Administration
- 8.3.3. Japan Companion Animal Postoperative Pain Management Therapeutics Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Animal
    - 8.3.3.2.2. By Product
    - 8.3.3.2.3. By Route of Administration
- 8.3.4. South Korea Companion Animal Postoperative Pain Management Therapeutics Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Animal
    - 8.3.4.2.2. By Product
    - 8.3.4.2.3. By Route of Administration
- 8.3.5. Australia Companion Animal Postoperative Pain Management Therapeutics Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Animal
    - 8.3.5.2.2. By Product
    - 8.3.5.2.3. By Route of Administration

9. Middle East & Africa Companion Animal Postoperative Pain Management Therapeutics Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Animal
- 9.2.2. By Product
- 9.2.3. By Route of Administration
- 9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Companion Animal Postoperative Pain Management Therapeutics Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Animal
    - 9.3.1.2.2. By Product
    - 9.3.1.2.3. By Route of Administration
- 9.3.2. UAE Companion Animal Postoperative Pain Management Therapeutics Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Animal
    - 9.3.2.2.2. By Product
    - 9.3.2.2.3. By Route of Administration
- 9.3.3. South Africa Companion Animal Postoperative Pain Management Therapeutics Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Animal
    - 9.3.3.2.2. By Product
    - 9.3.3.2.3. By Route of Administration

10. South America Companion Animal Postoperative Pain Management Therapeutics Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Animal
- 10.2.2. By Product
- 10.2.3. By Route of Administration
- 10.2.4. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Companion Animal Postoperative Pain Management Therapeutics Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Animal
    - 10.3.1.2.2. By Product
    - 10.3.1.2.3. By Route of Administration
- 10.3.2. Colombia Companion Animal Postoperative Pain Management Therapeutics Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Animal
    - 10.3.2.2.2. By Product
    - 10.3.2.2.3. By Route of Administration
- 10.3.3. Argentina Companion Animal Postoperative Pain Management Therapeutics Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Animal
    - 10.3.3.2.2. By Product
    - 10.3.3.2.3. By Route of Administration

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Companion Animal Postoperative Pain Management Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Zoetis Inc.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Merck & Co., Inc.
15.3. Elanco Animal Health Inc.
15.4. Ceva Sante Animale S.A.
15.5. Boehringer Ingelheim International GmbH
15.6. Norbrook Laboratories
15.7. Dechra Pharmaceuticals PLC
15.8. Chanelle Pharma
15.9. Bimeda Holdings Limited
15.10. VETOQUINOL S.A.